Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115472) titled 'Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder' on Aug. 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Xijing Hospital of Digestive Diseases
Condition:
Superior Mesenteric Artery Syndrome
Somatic Symptom Disorder (DSM-5)
Intervention:
Drug: Fluoxetine
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: January 1, 2024
Target Sample Size: 45
Countries of Recruitment:
China
To know more, visit ...